Latest Capital Raises News

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches PolePilot™, an AI-driven automation tool enhancing utility network analysis.

ikeGPS has reported a robust first half of FY26 with subscription revenue soaring 47%, a successful A$24 million capital raise, and inclusion in the ASX All Ordinaries Index, underscoring its expanding footprint in the US grid modernization market.

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches AI-driven PolePilot™ to boost productivity and ARPU.

Lion Rock Minerals has confirmed a major expansion of its mineralised footprint at the Minta Rutile and Monazite Projects in Cameroon, backed by significant funding rounds including a strategic partnership with Tronox Holdings. The company is well-positioned to accelerate exploration and resource definition into 2026.

Riedel Resources has finalized drilling plans for its high-grade Kingman Gold Project in Arizona and secured $1.4 million through equity raises to fund upcoming exploration and development activities.

Golden Dragon Mining Ltd is set to raise $5 million through an IPO, aiming for ASX listing with a portfolio of promising gold and nickel exploration projects in Western Australia.

Brazilian Critical Minerals Limited reported a net cash outflow of AUD 1.2 million for Q3 2025, offset by strong financing inflows that boosted its cash reserves to AUD 2.46 million. The company’s extended loan facility and available credit provide a runway of over five quarters at current spending levels.

Matsa Resources has commenced mining at its Devon Pit Gold Mine, producing over 2,600 ounces of gold, while securing a $15 million funding package to accelerate development of its Lake Carey Gold Project.

Adelong Gold Limited reports significant progress in Victorian exploration with maiden drilling confirming robust gold mineralisation, while navigating a joint venture deadlock in NSW and securing a $1.25 million strategic investment.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Pantera Lithium has completed the sale of its Smackover Lithium Project to EnergyX for A$40 million, securing cash and stock that bolster its balance sheet and strategic focus on US critical minerals.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.